Morgan Stanley
IRMD icon

Morgan Stanley’s iRadimed IRMD Stock Holding History

Morgan Stanley’s Portfolio IRMD Stock Details IRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.4M Buy
149,839
+15,108
+11% +$1.51M ﹤0.01% 3251
2025
Q4 		$13.1M Buy
134,731
+7,529
+6% +$646K ﹤0.01% 3357
2025
Q3 		$9.05M Buy
127,202
+35,732
+39% +$2.38M ﹤0.01% 3632
2025
Q2 		$5.47M Buy
91,470
+4,601
+5% +$252K ﹤0.01% 3992
2025
Q1 		$4.56M Sell
86,869
-1,161
-1% -$65.2K ﹤0.01% 4001
2024
Q4 		$4.84M Buy
88,030
+1,822
+2% +$95.9K ﹤0.01% 4028
2024
Q3 		$4.34M Sell
86,208
-2,357
-3% -$109K ﹤0.01% 4067
2024
Q2 		$3.89M Buy
88,565
+41,223
+87% +$1.75M ﹤0.01% 4092
2024
Q1 		$2.08M Sell
47,342
-97,880
-67% -$4.33M ﹤0.01% 4544
2023
Q4 		$6.89M Buy
145,222
+91,815
+172% +$3.86M ﹤0.01% 4174
2023
Q3 		$2.37M Buy
53,407
+14,016
+36% +$651K ﹤0.01% 4276
2023
Q2 		$1.88M Buy
39,391
+14,528
+58% +$655K ﹤0.01% 4463
2023
Q1 		$978K Sell
24,863
-11,031
-31% -$401K ﹤0.01% 4872
2022
Q4 		$1.02M Sell
35,894
-4,597
-11% -$132K ﹤0.01% 4860
2022
Q3 		$1.22M Sell
40,491
-9,107
-18% -$317K ﹤0.01% 4769
2022
Q2 		$1.68M Buy
49,598
+28,939
+140% +$1.04M ﹤0.01% 4663
2022
Q1 		$927K Sell
20,659
-8,330
-29% -$385K ﹤0.01% 5051
2021
Q4 		$1.34M Buy
28,989
+14,837
+105% +$599K ﹤0.01% 4869
2021
Q3 		$475K Buy
14,152
+1,183
+9% +$40.2K ﹤0.01% 5531
2021
Q2 		$381K Sell
12,969
-19,633
-60% -$541K ﹤0.01% 5692
2021
Q1 		$840K Sell
32,602
-26,736
-45% -$639K ﹤0.01% 4831
2020
Q4 		$1.35M Buy
59,338
+38,670
+187% +$894K ﹤0.01% 4464
2020
Q3 		$442K Sell
20,668
-13,751
-40% -$309K ﹤0.01% 4708
2020
Q2 		$798K Sell
34,419
-169
-0.5% -$3.63K ﹤0.01% 4332
2020
Q1 		$738K Buy
34,588
+19,875
+135% +$473K ﹤0.01% 4153
2019
Q4 		$344K Sell
14,713
-13,236
-47% -$309K ﹤0.01% 5137
2019
Q3 		$588K Buy
27,949
+14,831
+113% +$303K ﹤0.01% 4610
2019
Q2 		$268K Buy
13,118
+1,637
+14% +$38.6K ﹤0.01% 4893
2019
Q1 		$322K Sell
11,481
-6,967
-38% -$182K ﹤0.01% 4809
2018
Q4 		$451K Sell
18,448
-7,579
-29% -$204K ﹤0.01% 4849
2018
Q3 		$967K Buy
26,027
+595
+2% +$16.1K ﹤0.01% 4567
2018
Q2 		$528K Buy
25,432
+5,463
+27% +$96.6K ﹤0.01% 5060
2018
Q1 		$287K Sell
19,969
-3,967
-17% -$56.5K ﹤0.01% 5307
2017
Q4 		$362K Sell
23,936
-16,040
-40% -$204K ﹤0.01% 5152
2017
Q3 		$383K Buy
39,976
+11,248
+39% +$107K ﹤0.01% 5030
2017
Q2 		$247K Sell
28,728
-30,274
-51% -$258K ﹤0.01% 5221
2017
Q1 		$525K Buy
59,002
+22,557
+62% +$209K ﹤0.01% 4808
2016
Q4 		$405K Buy
36,445
+17,631
+94% +$190K ﹤0.01% 5047
2016
Q3 		$319K Buy
18,814
+5,082
+37% +$94.1K ﹤0.01% 4777
2016
Q2 		$299K Sell
13,732
-6,984
-34% -$126K ﹤0.01% 4732
2016
Q1 		$397K Buy
20,716
+5,801
+39% +$111K ﹤0.01% 4580
2015
Q4 		$418K Buy
14,915
+7,612
+104% +$215K ﹤0.01% 4660
2015
Q3 		$178K Sell
7,303
-23,477
-76% -$562K ﹤0.01% 5141
2015
Q2 		$716K Buy
30,780
+28,214
+1,100% +$515K ﹤0.01% 4447
2015
Q1 		$39K Buy
2,566
+1,648
+180% +$24.3K ﹤0.01% 5878
2014
Q4 		$12K Buy
918
+900
+5,000% +$7.77K ﹤0.01% 6176
2014
Q3 		$0 Buy
+18
New +$163 ﹤0.01% 6607

Other funds holding IRMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Copeland Capital Management Conshohocken, Pennsylvania $4.5B AUM 18.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $315M AUM 62.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley's IRMD Position: Q1 2026 in Review

Morgan Stanley increased its iRadimed (IRMD) stake by 11% in Q1 2026, buying an estimated $1.51M and bringing the position to 149,839 shares worth $14.4M. The position accounts for ﹤0.01% of the portfolio, ranked #3251.

Morgan Stanley first reported a position in IRMD in Q3 2014 and has held it in 47 quarters since. 228 funds tracked by Wall St. Rank hold IRMD as of Q1 2026.

  • Morgan Stanley held 149,839 shares of iRadimed worth $14.4M as of Q1 2026.
  • Morgan Stanley bought 15,108 iRadimed shares in Q1 2026, an estimated $1.51M.
  • iRadimed made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #3251 holding.
  • Morgan Stanley first reported a position in iRadimed in Q3 2014 and has held it in 47 quarters since.
  • 228 funds tracked by Wall St. Rank held iRadimed as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.